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Heterozygous FOXN1 Variants Cause Low TRECs and
Severe T Cell Lymphopenia, Revealing a Crucial
Role of FOXN1 in Supporting Early Thymopoiesis
Marita Bosticardo,1 Yasuhiro Yamazaki,1 Jennifer Cowan,2 Giuliana Giardino,3 Cristina Corsino,1
Giulia Scalia,4 Rosaria Prencipe,3 Melanie Ruffner,5 David A. Hill,5 Inga Sakovich,6 Irma Yemialyanava,6
Jonathan S. Tam,7 Nurcicek Padem,8 Melissa E. Elder,9 John W. Sleasman,10 Elena Perez,11
Hana Niebur,12 Christine M. Seroogy,13 Svetlana Sharapova,6 Jennifer Gebbia,14 Gary Ira Kleiner,14
Jane Peake,15 Jordan K. Abbott,16 Erwin W. Gelfand,16 Elena Crestani,17 Catherine Biggs,17,18
Manish J. Butte,19 Nicholas Hartog,20 Anthony Hayward,21 Karin Chen,22 Jennifer Heimall,5
Filiz Seeborg,23 Lisa M. Bartnikas,17 Megan A. Cooper,24 Claudio Pignata,3,25 Avinash Bhandoola,2,25
and Luigi D. Notarangelo1,25,*
FOXN1 is the master regulatory gene of thymic epithelium development. FOXN1 deficiency leads to thymic aplasia, alopecia, and nail
dystrophy, accounting for the nude/severe combined immunodeficiency (nu/SCID) phenotype in humans and mice. We identified
several newborns with low levels of T cell receptor excision circles (TRECs) and T cell lymphopenia at birth, who carried heterozygous
loss-of-function FOXN1 variants. Longitudinal analysis showed persistent T cell lymphopenia during infancy, often associated with nail
dystrophy. Adult individuals with heterozygous FOXN1 variants had in most cases normal CD4þ but lower than normal CD8þ
cell counts. We hypothesized a FOXN1 gene dosage effect on the function of thymic epithelial cells (TECs) and thymopoiesis and
postulated that these effects would be more prominent early in life. To test this hypothesis, we analyzed TEC subset frequency and
phenotype, early thymic progenitor (ETP) cell count, and expression of FOXN1 target genes (Ccl25, Cxcl12, Dll4, Scf, Psmb11, Prss16,
and Cd83) in Foxn1nu/þ (nu/þ) mice and age-matched wild-type (þ/þ) littermate controls. Both the frequency and the absolute count
of ETP were significantly reduced in nu/þ mice up to 3 weeks of age. Analysis of the TEC compartment showed reduced expression
of FOXN1 target genes and delayed maturation of the medullary TEC compartment in nu/þ mice. These observations establish a
FOXN1 gene dosage effect on thymic function and identify FOXN1 haploinsufficiency as an important genetic determinant of T cell
lymphopenia at birth.Introduction
The thymus is the central organ for the development of
adaptive immunity, since it houses all stages of Tcell differ-
entiation from bone marrow-derived early thymic progen-
itors (ETPs) to fully mature T cells ready for export to the
periphery. Development of a functional thymus is strictly
dependent on the expression of FOXN1, a member of the
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The Amedevelopment of epithelial cells in the thymus and
skin.1–3 The earliest stages of thymus development from
the third pharyngeal pouch are independent of Foxn1 dur-
ing early stages of mouse embryogenesis (E9.5–E11 days),
whereas Foxn1 expression is necessary for the development
of thymic epithelial cells (TECs) from day E11.5.1 In hu-
mans, FOXN1 expression has been reported in the third
pharyngeal pouch at week 6 of embryonic development,
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induces the expression of genes involved in TEC differen-
tiation and early lymphoid progenitor migration from
the bone marrow, such as Ccl25, Cxcl12, Dll4, and Scf.5,6
More recently, FOXN1 has been shown to directly regulate
the expression of genes involved in antigen processing and
thymocyte selection, such as Psmb11, Prss16, and Cd83.5
After the initial stages of TEC lineage specification,
continued FOXN1 expression is required for all the next
phases of TEC differentiation in embryonic life and early
after birth, as well as in adult animals to avoid thymic invo-
lution.6–8
Biallelic loss-of-function (LoF)FOXN1mutations result in
complete athymia, congenital alopecia, and nail dystrophy
in bothmice andhumans (MIM: 601705).9 This phenotype
was originally identified in nude mice, which lack thymus
and fur and have a severe combined immune deficiency
(SCID) phenotype.2 A homozygous Foxn1 mutation was
found to be responsible for the nude phenotype in mice,
but it was only in 1996 that the first two human siblings
with a similar phenotypewere described10 and 3more years
were required for their homozygous FOXN1 p.Arg255* mu-
tation to be identified.11 Subsequently, several additional
individuals carrying homozygous FOXN1 mutations and
presenting with the nude/SCID phenotype have been
described.12–15
Until now, heterozygous LoF FOXN1 gene variants in
humans have been associated only with nail dystrophy
in a proportion of individuals,16 but no immunological
studies were reported in these subjects. Thymus size and
weight are reduced and decrease in the ratio of medullary
thymic epithelial cells (mTECs) to cortical TECs (cTECs)
is accelerated inmice carrying heterozygous Foxn1 LoFmu-
tations, similar to what is observed in wild-type mice with
aging,15,16 but without major consequences on T lympho-
cyte development.5,7
We report here that heterozygous LoF FOXN1 gene vari-
ants are associatedwith low levels of Tcell receptor excision
circles (TRECs) and T cell lymphopenia at birth and
increased susceptibility to infections and persistent lym-
phopenia during infancy affecting predominantly CD8þ
T cells. Analysis of 22 adult subjects carrying heterozygous
LoF FOXN1 variants revealed normal T cell counts, aside
from CD8þ T cell lymphopenia, and nail dystrophy in
several of them. To obtain mechanistic insights into the
possible effects of FOXN1 gene dosage, we studied the
thymus of Foxn1nu/þ mice at prenatal and postnatal age
and observed a dramatic reduction in the frequency and ab-
solute count of ETPs and a severe reduction in the expres-
sion of all main transcriptional targets of FOXN1 in the
thymus during the first weeks of life, with a trend toward
normalization over time. Taken together, the study of hu-
mans and mice with heterozygous FOXN1 LoF mutations
indicates that FOXN1 gene dosage is most critical during
embryonic and early post-natal life, so that FOXN1 hap-
loinsufficiency causes low TRECs and T cell lymphopenia
at birth that progressively improves with age.2 The American Journal of Human Genetics 105, 1–13, September 5,Material and Methods
Human Subjects
Twenty-one newborns with low TREC levels on dried blood spots
collected during newborn screening for SCID (P1–P21 in Tables 1
and S1) were identified andmanaged according to local guidelines.
DNA sequencing and targeted analysis of SCID-associated genes
identified heterozygous FOXN1 variants (reported in Table 1
as compared to FOXN1 RefSeq accession number GenBank:
NM_003593 andNG_007260.1). Genetic studies identified hetero-
zygous FOXN1 variants in four additional infants (P22–P25 in
Table 1) with T cell lymphopenia and a history of serious infec-
tions in three of them (P22–P24). Peripheral blood samples
were obtained from 5 parents (P26–P30 in Table 1) who carried
the same heterozygous FOXN1 variant as their offspring and
from 17 adult subjects from the village of Acerno (Italy) who
had been previously found to carry the heterozygous FOXN1
p.Arg255* mutation.16 Written informed consent was obtained
from the adult subjects and, in the case of minors, from their
parents and/or legal guardians, in compliance with protocols
approved by the local Institutional Review Board and the NIH pro-
tocol 18-I-0041. Normal range and median values for each periph-
eral blood cell subset, at different age ranges, were obtained from
Shearer et al.17
Mice
Heterozygous Foxn1nu/þ mice (obtained from Jackson Labora-
tories) were bred with wild-type (WT) C57BL/6 mice to generate
mixed litters of Foxn1nu/þ (hereafter called ‘‘nu/þ’’) and Foxn1
wild-type (hereafter called ‘‘þ/þ’’) mice. Most experiments were
conducted blindly as genotype was often determined after the
flow cytometry and qPCR data were obtained. Animal work was
conducted in specific-pathogen-free conditions, in accordance to
the USPHS Policy on Humane Care and Use of Laboratory Animals
with an animal study protocol approved by the NIAID Animal
Care and Use Committee (protocol LCIM 6E).
Thymus Cell Isolation
Thymuswas isolated from littermate nu/þ andþ/þmice of various
ages (from E15.5 embryos to 5-week-old mice). For the isolation of
thymocytes, thymic tissue was mashed in FACS Buffer, made with
PBS (GE Healthcare Bio-Sciences) supplemented with 2% FBS
(Gemini Bio-Products) and 0.2% Primocin (InvivoGen). Cells
were then filtered through 40 mm cell strainers (VWR), counted,
and kept on ice until use. To isolate TECs, the thymus was
dissected free from fat and stromal tissue and then digested
at 37C (three steps of 5 min each) with a solution containing
Liberase TL (Sigma-Aldrich) and DNase I (Sigma-Aldrich). Digested
thymic cells were recovered in IMDM (Iscove’s Modifed Dulbecco
Medium, GIBCO, Thermo Fisher Scientific) supplemented with
10% FBS and Primocin. Thymic epithelial cells (TECs) were fur-
ther enriched by depleting CD45þ cells with the AutoMACS
ProSeparator (Miltenyi Biotec), after incubating digested thymic
cells with anti-CD45 microbeads (Miltenyi Biotec). TECs were
used immediately for staining and FACS analysis or pelleted and
stored at 80C for gene expression studies.
Flow Cytometry
For flow cytometry analysis, thymocytes were stained with the
following antibodies (all from BioLegend): anti-CD4 FITC (clone
RM4-5), anti-CD8 APC (clone 53-6.7), anti-CD44 PE-Cy7 (clone2019
Table 1. Genetic and Clinical Features of 47 Individuals with Heterozygous FOXN1 Variants
Pt ID Sex
Current
Age
(years) Varianta Protein Effect MAF
CADD
Score
Thymic
Shadow
Nail
Dystrophy Infections
Other Clinical
Manifestations,
Treatment
P1 M 1 c.505G>A p.Glu169Lys 0 31 present N rhinovirus,
enterovirus
none
P2 M 2 c.907_907delG p.Glu303Serfs*247 0 35 ND Y none none
P3 M 1 c.958C>T p.Arg320Trp 3.19e5 35 small N rhinovirus, URTI none
P4 F 4 c.961C>A p.His321Asn 0 29.4 small Y rhinovirus, otitis atopic dermatitis,
HSCT
P5 F 3 c.1009_1009delG p.Gly337Glufs*
213
0 34 ND N URTI skin rash
P6 M 1 c.1086_1087insA p.Trp363Metfs*
118
0 34 present N URTI none
P7 F 2 c.1135þ5G>C NA 3.21e5 3.25 absent N gastroenteritis foot polydactyly,
abnormal skin
P8 F 3 c.1168_1168delG p.Glu390Lysfs*
160
0 32 ND Y RSV, influenza,
AOM, pneumonia
none
P9 F 4 c.1201_1216del16 p.Pro401Alafs*144 0 35 absent N URTI none
P10 M 2 c.1201_1216del16 p.Pro401Alafs*144 0 35 ND N none atopic dermatitis
P11 F 2 c.1201_1216del16 p.Pro401Alafs*144 0 35 ND N none atopic dermatitis
P12 F 2 c.1201_1216del16 p.Pro401Alafs*144 0 35 absent N none eczema
P13 M 4 c.1201_1216del16 p.Pro401Alafs*144 0 35 ND Y none none
P14 M 3 c.1205_1205delC p.Pro402Leufs*
148
4.049e6 27.9 ND Y RSV, rhinovirus,
pneumonia
thin hair,
eosinophilia
P15 M 2 c.1206delT p.Leu404Cysfs*
146
0 25.6 ND Y none none
P16 M 1 c.1315_1315delC p.Leu439Cysfs*
111
0 32 present N URTI VSD
P17 M 2 c.1315_1315delC p.Leu439Cysfs*
111
0 32 absent N URTI VSD
P18 F 1 c.1316_1316delT p.Leu439Argfs*
111
0 32 ND N none none
P19 F 4 c.1418_1418delC p.Pro473Hisfs*77 0 34 small Y rhinovirus,
norovirus
thin hair, HSCT
P20 F 1 c.1420C>T p.Gln474* 0 37 ND Y URTI none
P21 M 2 c.1584_1584delC p.Leu529Trpfs*21 0 27.8 ND N rhinorrhea,
diarrhea
none
P22 M 2 c.974T>C p.Leu325Pro 0 27.2 small N norovirus, RSV,
rhinovirus,
sapovirus,
C. difficile,
rotavirus,
Parainfluenzae
pneumonia,
corynebacterium
arthritis,
hypertension,
anemia, failure to
thrive,skin rashes,
proteinuria,
thrombocytopenia,
bleedings
P23 F 9 c.1392_1401del10 p.Pro465Argfs*82 0 34 small Y bronchitis,
omphalitis,
Candidiasis, CMV,
Molluscum
DLBCL (EBVþ),
malabsorption
P24 M 5b c.1392_1401del10 p.Pro465Argfs*82 0 34 small Y enterocolitis,
pneumonia,
CMV,
HHV6
HSCT (deceased
2y later)
P25 M 4 c.1850_1854del5 p.Tyr617Cysfs*
157
0 35 ND N URTI TEF
(Continued on next page)
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Table 1. Continued
Pt ID Sex
Current
Age
(years) Varianta Protein Effect MAF
CADD
Score
Thymic
Shadow
Nail
Dystrophy Infections
Other Clinical
Manifestations,
Treatment
P26 F 22 c.1201_1216del16 p.Pro401Alafs*144 0 35 ND N otitis, pneumonia none
P27 F 30 c.907_907delG p.Glu303Serfs*247 0 35 ND N none none
P28 F 37 c.1206delT p.Leu404Cysfs*
146
0 25.6 ND Y none none
P29 F 40 c.1201_1216del16 p.Pro401Alafs*144 0 35 ND Y none none
P30 F 40 c.1168_1168delG p.Glu390Lysfs*
160
0 32 ND Y RRTI none
P31 M 29 c.763C>T p.Arg255* 3.98e6 38 ND Y none none
P32 F 38 c.763C>T p.Arg255* 3.98e6 38 ND Y none seborrheic dermatitis,
pituitary adenoma
P33 F 39 c.763C>T p.Arg255* 3.98e6 38 ND Y sinusitis eczema, multiple
dental cavities
P34 F 40 c.763C>T p.Arg255* 3.98e6 38 ND N none eczema, multiple
dental cavities
P35 F 41 c.763C>T p.Arg255* 3.97e6 38 ND N none osteoporosis
P36 F 42 c.763C>T p.Arg255* 3.98e6 38 ND Y otitis, sinusitis none
P37 F 45 c.763C>T p.Arg255* 3.98e6 38 ND N none eczema,
rhinoconjunctivitis
P38 F 48 c.763C>T p.Arg255* 3.98e6 38 ND Y none multiple dental
cavities
P39 F 53 c.763C>T p.Arg255* 3.98e6 38 ND Y candidiasis,
sinusitis,
gastroenteritis
multiple dental
cavities, melanoma,
cardiac arrhythmias
P40 M 55 c.763C>T p.Arg255* 3.98e6 38 ND Y none androgenic, hair loss
P41 M 57 c.763C>T p.Arg255* 3.98e6 38 ND Y none mental retardation,
multiple dental
cavities, androgenic
P42 M 58 c.763C>T p.Arg255* 3.98e6 38 ND N none rosacea, multiple
dental cavities
P43 F 59 c.763C>T p.Arg255* 3.98e6 38 ND N none none
P44 F 59 c.763C>T p.Arg255* 3.98e6 38 ND Y none none
P45 M 60 c.763C>T p.Arg255* 3.98e6 38 ND Y none androgenic, hair loss
P46 M 62 c.763C>T p.Arg255* 3.98e6 38 ND Y none eczema, multiple
dental cavities,
ocular thrombosis
P47 F 69 c.763C>T p.Arg255* 3.98e6 38 ND Y otitis Chiari malformation
Abbreviations: AOM, acute otitis media; CADD, combined annotation dependent depletion; CMV, cytomegalovirus; DLBCL, diffuse large B cell lymphoma; EBV,
Epstein-Barr virus; F, female; HHV6, human herpes virus 6; HSCT, hematopoietic stem cell transplantation; M, male; MAF, minor allele frequency (calculated ac-
cording to the GnomAD database, v.2.1.1); N, no; NA, not assessed; ND, not done; RRTI, recurrent respiratory tract infection; RSV, respiratory syncytial virus; TEF,
tracheesophageal fistula; URTI, upper respiratory tract infection; VSD, ventricular septal defect; Y, yes.
aFOXN1variants named using GenBank transcripts NM_003593 and NG_007260.1
bDeceased
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PC61), and anti-mouse Lineage cocktail Pacific Blue (17A2/RB6-
8C5/RA3-6B2/Ter-119/M1/70).
To evaluate TEC phenotype, MACS-purified CD45-negative
cells were incubated with the following antibodies: anti-CD45
PE-Cy7 (clone 30-F11, BioLegend), anti-EpCam PerCP-Cy5.5
(clone G8.8, BioLegend), anti-Ly51 PE (clone 6C3, Miltenyi Bio-
tec), anti-MHC class II APC-Cy7 (clone M5/114.15.2, BioLegend),
and anti-Ulex Europeaus Agglutinin I (UEA I) (clone FL-1061, Vec-4 The American Journal of Human Genetics 105, 1–13, September 5,tor Laboratories) antibodies. Live/Dead Fixable Yellow (Thermo
Fisher Scientific) was added to the antibody mix to exclude dead
cells.
Events were acquired on an LSR Fortessa flow cytometer (BD Bio-
sciences) and analyzed using FlowJo software v.10.5.2 (FlowJo).
Gene Expression
RNA was extracted from TECs using the RNeasy Micro kit
(QIAGEN) and stored at 80C until used. Reverse transcription2019
Figure 1. FOXN1 Domains with Location
of the Mutations
Mutations previously published as causing
nude/SCID phenotype in subjects are indi-
cated in red in the upper part of the figure.
Heterozygous variants identified in the sub-
jects included in this study are indicated in
black in the lower part of the figure.
Numbers on top of the domains indicate
the amino acid number in FOXN1 protein.
Abbreviations: N-term, N-terminal; FKD,
Forkhead domain; C-term, C-terminal; TA,
transactivation domain.
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thesis kit (Quanta BioSciences). Real-time PCR for EpCam, Ccl25,
Cxcl12, Dll4, Scf, Psmb11, Prss16, and Cd83 gene expression was
performed with Perfecta SYBR Green FAST Mix LowRox (Quanta
BioSciences) inMicroAmpOptical 96-well reaction plates (Applied
Biosystems) in a final volume of 20 mL and run on the 7500 Real-
Time PCR machine (Applied Biosystems). Relative quantification
of gene expression was performed with the 2-DDCt method,
normalized to Epcam and expressed as fold change relative to
Epcam expression. Subsequently, for each gene we calculated the
average value obtained in all samples from þ/þ mice at each
time point, and relative gene expression was calculated by
dividing values in individual þ/þ and nu/þ mice for the average
value in þ/þ mice.
Statistical Analyses
All datasets were analyzed using GraphPad Prism software and ex-
pressed as mean 5 SD. Statistical significance was assessed using
the Mann-Whitney test, as indicated in each panel. p values <
0.05 were considered significant.Results
Heterozygous FOXN1 Variants in Newborns with Low
TRECs and T Cell Lymphopenia at Birth
We report here 25 pediatric subjects carrying heterozygous
FOXN1 variants (P1 through P25 in Table 1). Twenty-one
of them (P1–P21) were identified through abnormally
low TREC levels at newborn screening for SCID and were
confirmed to have T cell lymphopenia (Table S1), while
the remaining four pediatric subjects (P22–P25) were
identified based on a clinical phenotype of severe or recur-
rent, early-onset infections and T cell lymphopenia. The
heterozygous FOXN1 variants were identified by DNA
sequencing when these infants were investigated for
SCID-associated gene variants, according to policies in
place at the referring institutions. No disease-causing
variants in other SCID-associated genes were identified.
Twenty-two adult subjects (P26 through P47, Table 1)
with heterozygous FOXN1 variants were also studied and
included 5 parents of the 25 pediatric subjects, as well as
17 individuals from the village of Acerno, Italy, known to
be heterozygous for the FOXN1 p.Arg255* mutation.16 In
total, 20 distinct FOXN1 gene variants were identified
(Table 1 and Figure 1). Three of these variants have beenThe Amereported at very low frequency (minor allele frequency <
3.19 3 105) in the general population. The remaining
17 variants have not been reported in GnomAD or in
1000 Genomes (Table 1). The majority (n ¼ 13) of
FOXN1 variants (65%) were frameshift, four (20%) were
missense, and the remaining three were either nonsense
(n ¼ 2, 10%) or splice-site (n ¼ 1, 5%) variants. As shown
in Figure 1, the variants spanned FOXN1, but 6 of them
were clustered in the forkhead domain (FKD, amino acid
271–366) and 12 in the C-terminal domain. One of the
latter (p.Leu529Trpfs) is located in the transactivation
domain.
Athymia has been reported in individuals carrying ho-
mozygous LoF FOXN1 mutations.7 In our cohort of 25 in-
fants with heterozygous FOXN1 variants, presence of the
thymic shadow on chest X-ray was evaluated in 13 individ-
uals. Among these, 10 showed absent or reduced thymic
shadow, while a normal-sized thymic shadow was detected
in 3 infants (Table 1). Infections were reported in 18
FOXN1þ/ infants (72%) and were of viral origin in most
of them (Table 1). Upper respiratory tract infections were
particularly common. Five infants had a history of pneu-
monia, and protracted watery diarrhea due to norovirus
infection was recorded in two other infants. Finally, recur-
rent, severe infections occurred in five individuals (P8, P14,
P22–P24), and one of them (P23) developed EBV-positive
diffuse large B cell lymphoma. By contrast, a significant
history of recurrent infections was documented only in a
minority (6/22, 27.3%) of adult individuals with heterozy-
gous FOXN1 variants. Only one subject (P22) presented
with autoimmunity (severe thrombocytopenia). Nail dys-
trophy is another typical feature of FOXN1 deficiency.9
In our cohort, nail dystrophy was documented in 10/25
(40%) infants and in 15/22 (68.2%) adults with heterozy-
gous FOXN1 variants. No infants had alopecia universalis
(another common feature of FOXN1 deficiency), but thin
hair was reported in two infants and hair loss in two adults.
Eczema and other cutaneous manifestations of atopic
dermatitis were documented in seven infants and five
adults. Most infants were managed conservatively. How-
ever, three of them (P4, P19, and P24) received HSCT
before the FOXN1 variants were identified. In P4 and
P19, HSCTwas motivated by the extreme T cell lymphope-
nia (14 and 11 CD3þ cells/mL in P4 and P19, respectively)rican Journal of Human Genetics 105, 1–13, September 5, 2019 5
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Figure 2. Lymphocyte Counts in Individuals Carrying Heterozygous LoF FOXN1 Variants
The graphs show total absolute lymphocyte counts (ALC) (A), CD19þ (B), CD16þ/CD56þ (C), CD3þ (D), CD4þ (E), CD8þ (F), CD4þ
CD45RAþ (G), and CD8þCD45RAþ (H) cell counts indicated as counts/mL at different ages (0–3 months, 3–6 months, 7–12 months,
13–24 months, 3–10 years, adult). Gray areas indicate normal ranges. Each subject is represented by a dot of the same color at the
different age ranges.
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stem cell engraftment, both individuals remained T cell
lymphopenic after transplantation. P24 was referred to
HSCT because of a history of severe infections and died
of transplant-related complications 2 years after HSCT.
Immunological investigations showed that the lympho-
penia was present in the majority of FOXN1þ/ infants at
diagnosis (Figure 2A and Table S1) and reflected a lower
than normal number of CD3þ T cells that included
both CD4þ and CD8þ T cells, and their naive (CD45RAþ)
subsets (Figures 2D–2H). By contrast, no abnormalities6 The American Journal of Human Genetics 105, 1–13, September 5,were observed in the number of CD19þ B cells and CD3
CD56/16þ NK cells (Figures 2B and 2C). Longitudinal ana-
lyses of T cell counts over time in the pediatric cohort
showed that CD4þ T cell lymphopenia persisted in most
infants, but the severity of the defect was less pronounced
beyond the first 2 years of age, while CD8þ Tcell counts re-
mained stably below the normal range inmost infants (Fig-
ures 2E and 2F). While the absolute lymphocyte count
(ALC) and total CD3þ and CD4þ T cell counts were within
the normal range in most of the adults with heterozygous
LoF FOXN1 variants (Figures 2A, 2D, and 2E), the absolute2019
Figure 3. Total Thymocyte Counts and Early Thymic Progenitor (ETP) Counts and Frequency in nu/þ and þ/þ Mice
(A) Graph shows thymocyte absolute counts in nu/þ (red squares) and þ/þmice (blue dots) at different ages (d, day; w, weeks). Number
of mice analyzed at each time point: 1d (þ/þ, n¼ 13; nu/þ, n¼ 11), 5d (þ/þ, n¼ 8; nu/þ, n¼ 7), 2w (þ/þ, n¼ 14; nu/þ, n¼ 8), 3w (þ/þ,
n ¼ 13; nu/þ, n ¼ 9), 5w (þ/þ, n ¼ 6; nu/þ, n ¼ 6). Mean5 SD are represented. ns, not significant, **p < 0.01; Mann-Whitney test.
(B) Representative flow cytometry plots of early thymic progenitors (ETPs), identified as CD44þcKitþ, gated on LineageCD25 thymo-
cytes, at different ages (3 days, 6 days, 3 weeks) inþ/þmice (upper row) and in nu/þmice (lower row). Numbers on the plots indicate the
frequency of ETPs.
(C and D) Graphs show ETP frequencies (C) and absolute counts (D) for allþ/þ and nu/þmice analyzed at the different ages. Number of
mice analyzed at each time point: 1d (þ/þ, n ¼ 19; nu/þ, n ¼ 14), 5d (þ/þ, n ¼ 8; nu/þ, n ¼ 7), 2w (þ/þ, n ¼ 11; nu/þ, n ¼ 7), 3w (þ/þ,
n¼ 12-13; nu/þ, n¼ 9), 5w (þ/þ, n¼ 6; nu/þ, n¼ 6). Mean5 SD are represented. ns, not significant, *p< 0.05, **p< 0.01, ***p< 0.001;
****p < 0.0001; Mann-Whitney test.
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(Figure 2F). Consistent with these data, the proportion of
individuals with lower than normal ALC, CD3þ, and
CD4þ T cell counts progressively declined with age and
eventually resolved (Figures 2E and S1), whereas normali-
zation of CD8þ T cell counts occurred in only a minority
of subjects, and most adults remained with a low number
of naive CD8þ T cells (Figures 2H and S1). Finally, around
30% of the adults had a lower than normal proportion of
naive CD45RAþCD4þ cells (Figure 2G), suggesting that
normalization of the total CD4þ Tcell counts in adulthood
is contributed by homeostatic proliferation. Together,
these data indicate that FOXN1 haploinsufficiency is asso-
ciated with T cell lymphopenia in infancy and that the
CD8þ T cell compartment is principally affected.
Nu/þMice Have Dramatically Reduced Frequencies and
Absolute Numbers of ETPs Only in the First 3 Weeks
of Life
To determine whether the immune status of nu/þ mice at
birth recapitulates the findings in FOXN1þ/ infants, we
analyzed thymocyte counts in nu/þmice and age-matchedThe Amelittermate wild-type (þ/þ) controls at various time points
after birth: 1–3 days, 5–6 days, 2 weeks, 3 weeks, and
5 weeks. Thymocyte numbers were only slightly reduced
at 2 and 3 weeks after birth in nu/þmice (Figure 3A). How-
ever, as compared to þ/þ littermate controls, nu/þ mice
had a dramatic reduction in the frequency and absolute
count of ETPs (identified as CD45þLinCD25CD44þ
cKitþ cells) (Figures 3B and 3C), indicative of reduced
migration of lymphoid progenitors to the thymus through
5 weeks of age, when both the frequency and the count of
thymic ETPs were comparable in nu/þ and þ/þ mice (Fig-
ures 3C and 3D).
TECs of nu/þMice Display an Immature Phenotype and
Express Significantly Lower Levels of FOXN1 Target
Genes during Embryonic Development and Early in
Post-natal Life
To investigate the impact of Foxn1 haploinsufficiency on
TEC maturation and function, we set out to analyze the
TEC compartment in nu/þ mice and þ/þ littermate con-
trols during embryonic development and at various time
points early after birth. After digestion of thymic tissuerican Journal of Human Genetics 105, 1–13, September 5, 2019 7
Figure 4. TEC Phenotype in nu/þ and þ/þ Mice
(A) Representative flow cytometry plots of TECs gated on CD45EpCamþ cells in þ/þ (upper row) and nu/þmice (lower row). Cortical
TEC (cTEC) are identified as Ly51þUEA I and medullary TEC (mTEC) as Ly51UEA Iþ. Numbers in the plots indicate the frequency of
cTEC and mTEC at the different ages (d, day; w, weeks).
(B) Graph shows the frequency of mTEC in all þ/þ and nu/þ mice analyzed at the different ages. Mean5 SD are represented. ns, not
significant, *p < 0.05, **p < 0.01; Mann-Whitney test.
(C) Graph shows the ratio between mTEChi and mTEClo in þ/þ and nu/þ mice at each age analyzed. Mean 5 SD are represented.
*p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001; Mann-Whitney test.
(D) Graph shows the absolute counts of mTEChi in þ/þ and nu/þ mice at each age analyzed. Mean5 SD are represented. ns, not sig-
nificant, *p < 0.05, **p < 0.01; Mann-Whitney test.
(B–D) Number of mice analyzed at each age: 1d (þ/þ, n¼ 9; nu/þ, n¼ 11), 4–7d (þ/þ, n¼ 15; nu/þ, n¼ 8), 2w (þ/þ, n¼ 8; nu/þ, n¼ 3),
3w (þ/þ, n ¼ 10; nu/þ, n ¼ 8), 5w (þ/þ, n ¼ 6; nu/þ, n ¼ 6).
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flow cytometry to characterize TEC phenotype and quanti-
tative PCR (qPCR) to evaluate their gene expression profile.
TECs were identified as CD45EpCamþ cells and further
divided into Ly51þUEA I cTECs and Ly51UEA IþmTECs8 The American Journal of Human Genetics 105, 1–13, September 5,(Figure 4A). Compared to þ/þ littermate controls, nu/þ
mice showed a slight reduction in mTEC frequency, which
was significant at 2 and 3 weeks of age (Figure 4B). The
density of MHC class II (MHC-II) antigen expression has
been used to distinguish mTECs at different stages of2019
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pressing lower levels of MHC-II antigens (mTEClo) are
considered to represent a less mature stage of differentia-
tion as compared to mTECs expressing high levels
of MHC-II (mTEChi).18,19 In nu/þ mice, the reduction of
mTEC numbers was more apparent in the subset of
mTEChi cells, as shown by the reduced ratio of mTEChi
to mTEClo cells (Figure 4C) and by the reduced absolute
count of mTEChi cells (Figure 4D) as compared with þ/þ
littermate controls. These data indicate that TECs from
nu/þ mice have a less mature phenotype than the þ/þ
mice.
We then analyzed the expression profile of several key
FOXN1-target genes (Ccl25, Cxcl12, Dll4, Scf, Psmb11,
Prss16, andCd83) whose expression is critical for TEC func-
tion, including recruitment of ETPs and positive selection
of CD8þ and CD4þ thymocytes. As shown in Figure 5,
for all of these genes, during embryonic development,
nu/þ mice had lower levels of expression than þ/þ litter-
mate controls. For several genes (Ccl25, Cxcl12, Psmb11,
and Cd83), this difference remained significant even at
the last time point (week 5 of life), and a similar trend
was observed forDll4, Scf, and Prss16, albeit without reach-
ing statistical significance. In summary, our data indicate
that mouse Foxn1 haploinsufficiency has important effects
on TEC maturation and function and that these effects are
most evident during embryonic development and in the
first weeks of life.Discussion
We present here evidence that rare heterozygous LoF vari-
ants in the FOXN1 gene are associated with low TRECs and
T cell lymphopenia at birth and early in childhood.
The FOXN1 gene is considered loss-of-function intol-
erant with a pLI score of 0.94 in the genome aggregation
database (GnomAD). To date, ten subjects carrying three
distinct homozygous FOXN1 mutations have been re-
ported and they all manifested a complete nude pheno-
type.10,12–15 The mutation found in the original two
individuals and subsequently in six additional infants is
a nonsense mutation at position 255.10,12,13,15 The other
two mutations were found only in one subject each and
include a frameshift mutation at position 18814 and a
missense mutation at position 320 (p.Arg320Trp).13 Both
the p.Arg255* and the p.Ser188fs mutations result in loss
of protein expression due to mRNA decay.11,14 The
missense p. Arg320Trp mutation falls in the FKD and af-
fects an amino acid residue that is highly conserved among
species20,21 and that plays a critical role in binding at the
GACGC FOXN1 consensus sequence.22
In this manuscript, we have reported a total of 19
distinct FOXN1 heterozygous variants in 25 infants. One
of these variants (p.Arg320Trp) was previously described
in one individual with biallelic FOXN1 mutation and a
nude phenotype.13 Among the remaining new 18 variants,The Amethemajority (13 out 18, 72.2%) were frameshift mutations,
one affected a splice site, and one was nonsense. Because
of their nature, all of these are predicted to be delete-
rious. The remaining three variants were missense: two
(p.His321Asn and p.Leu325Pro) are also located in the
FKD, like the p.Arg320Trp mutation. In particular,
FOXN1 residue His321 has been recently shown to be
directly involved, together with Arg320, in binding of
the FOXN1 DNA consensus sequence.20 The last missense
variant (c.505G>A [p.Glu169Lys]) is located in the N-ter-
minal domain, and its impact on FOXN1 expression and
function remains to be investigated. Overall, the nature
of the FOXN1 variants identified in this series suggests
that they are most likely LoF. However, the possibility
that alleles disrupting the C-terminal domain but retaining
the FKD domain intact might act as dominant-negative
mutants23 cannot be formally excluded.
Most of the infants with heterozygous FOXN1 variants
included in this study were identified at birth following
detection of out-of-range TREC levels during newborn
screening for SCID and were confirmed to have T cell lym-
phopenia. Longitudinal follow up of these infants during
the first years of life revealed persistence of CD8þ T cell
lymphopenia and a trend toward improvement of the
CD4þ T cell count. In some individuals, these immunolog-
ical abnormalities were associated with recurrent infec-
tions, which were particularly severe in a few. The nail
dystrophy was initially overlooked in most of the subjects
and was recognized only in a proportion of them after
identification of FOXN1 haploinsufficiency prompted a
more careful physical examination. In a previous study
of adults heterozygous for the FOXN1 p.Arg255* mutation,
the nail dystrophy was not immediately obvious on
examination and was often restricted to toenails.16 To bet-
ter assess the immunological and clinical impact of FOXN1
haploinsufficiency in adulthood, we studied 22 adults who
are heterozygous for the FOXN1 c.763C>T (p.Arg255*)
mutation or for the same variant identified in their
offspring. Our data demonstrate that most of these indi-
viduals had a normal CD4þ T cell count and were not
unduly susceptible to recurrent infections; however, most
of them had a low CD8þ T cell count and 60% of them
showed nail dystrophy. These data indicate that FOXN1
haploinsufficiency causes a marked T cell lymphopenia
early in life, followed by progressive normalization of the
CD4þ T cell count but persistence of CD8þ T cell lympho-
penia that may extend into adulthood. The mechanisms
accounting for a differential effect of FOXN1 haploinsuffi-
ciency on CD4þ and CD8þ T cell numbers with age are un-
clear. One possibility is that FOXN1 gene dosage has amore
stringent role on the expression of genes involved in devel-
opment of CD8þ Tcells, such as PSMB11. Alternatively, ho-
meostatic proliferation might be more prominent for
CD4þ than for CD8þ T cells. There is evidence that the re-
quirements for homeostatic proliferation are different for
CD4þ versus CD8þ T cells.24 The observation that most
adults with heterozygous LOF FOXN1 variants had arican Journal of Human Genetics 105, 1–13, September 5, 2019 9
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Figure 5. Gene Expression Profile of TEC in nu/þ and þ/þ Mice
Graphs show gene expression ofCcl25 (A),Cxcl12 (B),Dll4 (C), Scf (D), Psmb11 (E), Prss16 (F), andCd83 (G) in TEC enriched after thymus
digestion and CD45-positive cell depletion in þ/þ and nu/þ mice at different ages (d, day; w, weeks). Relative quantification of gene
expression was performed with the 2-DDCt method, normalized to EpCam and expressed as fold change relative to EpCam. Subse-
quently, for each gene we calculated the average value obtained in all samples from þ/þmice at each age, and relative gene expression
was calculated by dividing values in individual þ/þ and nu/þmice for the average value in þ/þmice. Number of mice analyzed at each
time point: embryos (þ/þ, n ¼ 3-8; nu/þ, n ¼ 6–8), 1–5d (þ/þ, n ¼ 11–13; nu/þ, n ¼ 10–13), 2–3w (þ/þ, n ¼ 9–11; nu/þ, n ¼ 5–7), 5w
(þ/þ, n ¼ 6; nu/þ, n ¼ 6). Mean5 SD are represented. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001; ****p < 0.0001; Mann-
Whitney test.
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tion of naive (CD45RAþ) CD4þ cells is consistent with the
hypothesis that normalization of total CD4þ cell count
with age is contributed by homeostatic proliferation.
Studies in mice have shown that the initial stages of TEC
specification during embryogenesis are independent of
FOXN1,20,25 while all the subsequent steps of TEC differen-
tiation and growth are dependent on the continuous
expression of Foxn1, both during embryonic and in post-
natal life.6–8 Persistence of Foxn1 expression during adult-
hood is necessary to avoid or delay thymic involution.7,8
Previous studies have analyzed expression of FOXN1-
target genes in mice carrying hypomorphic Foxn1 alleles
that allow lower expression levels than in nu/þ mice.5–7
We report here evidence of reduced expression of
FOXN1-target genes during embryonic development and
early after birth in Foxn1 haploinsufficient mice. In partic-
ular, we detected a dramatic decrease in the frequency
and absolute counts of ETPs that was limited to the first
3 weeks of life. FOXN1 is a well-known inducer of
CCL25, CXCL12, and SCF secretion by TECs.5 Of these,
CCL25 and CXCL12 are critical attractants for lymphoid
progenitors migrating from the bone marrow to the
thymus,5,26 while SCF is a major growth factor driving
expansion of immature thymocytes.27,28 Expression of all
these three genes was strongly reduced in nu/þ mice. In
addition, the expression of Dll4, a direct target of
FOXN15 and a critical factor for the commitment of early
thymic progenitors to T cell development,29,30 was also
greatly reduced in nu/þ animals.
Finally, FOXN1 is also involved in the induction of genes
that play an important role in later steps of TEC-thymocyte
cross-talk, such as antigen processing (Psmb11 and Prss16)
and presentation (Cd83).5 Expression of all these genes was
also greatly reduced in TEC from nu/þ mice. Importantly,
the most significant differences in expression levels were
found in TEC isolated from nu/þ mice embryos and in
the first week of life. These data may also account for a
more significant impact of Foxn1 haploinsufficiency on
ETP count in the first weeks of life. In addition to reduced
gene expression in TECs of nu/þ mice, we also detected a
reduced frequency of mTECs, affecting in particular
mTEChi cells. A similar effect on mTEChi cells had previ-
ously been reported in other mouse models expressing
decreased levels of FOXN1.5,7 Together, our observations
in humans and mice suggest that the levels of FOXN1
needed for optimal thymic function and for CD4þ and
CD8þ Tcell development are different in embryonic versus
early post-natal life and adulthood. A possible explanation
for the time-dependent effects of FOXN1 gene dosage
comes from the recent observation that FOXN1 binding
to the DNA consensus sequence GACGC in the promoter
of target genes is influenced by the methylation status of
the CpG dinucleotide, such that binding occurs signifi-
cantly less tightly if the CpG is methylated.20 Since
increased promoter methylation is known to occur with
aging,31 the altered epigenetic status of FOXN1 target se-The Amerquences may play a role for a less pronounced FOXN1
gene dosage effect in older individuals.
Consistent with the observation that the thymus is
smaller in nu/þ than in þ/þ mice,32,33 we have docu-
mented mild defects in thymocyte numbers in nu/þ
mice. A more significant reduction in thymocyte counts
has been reported in mice with hypomorphic Foxn1 vari-
ants allowing lower levels of protein expression than
nu/þmice.5–7 In any case, the lymphopenia at birth in in-
dividuals carrying heterozygous LoF FOXN1 variants was
more profound than that of nu/þ mice, suggesting that
FOXN1 haploinsufficiency is responsible for a more severe
phenotype in humans than in mice.
Both thymus transplantation and HSCT have been pre-
viously used to treat individuals with bi-allelic FOXN1mu-
tations and a nude phenotype. Three individuals received
unmanipulated T cell-replete HSCT from HLA-matched
siblings. Reconstitution of the T cell count was observed
in one, who was reported to be alive and infection-free
6 years after transplantation; however, CD4þ T cells were
unable to proliferate.34 The other two individuals who
received HSCT died of complications post-transplant.14,15
Two individuals received thymus transplantation; both
had a slower T cell reconstitution, but eventually attained
normal T cell counts, with capacity to generate naive
CD4þ T cells, normal in vitro T cell proliferative responses
to mitogens, and reconstitution of antibody production.
These subjects were reported to be alive and infection-
free at 3 and 5 years after transplantation, respec-
tively,13,35 although one of them developed autoimmune
hypothyroidism and vitiligo.36
Three of the infants included in this study underwent
HSCT either before the genotype was known or because
it was thought that FOXN1 haploinsufficiency was not a
likely cause of the T cell lymphopenia. However, none of
them normalized the T cell count or reversed the clinical
phenotype after transplantation, indicating that the defect
was extrinsic to the hematopoietic lineage.
Our results have important implications for the diag-
nosis and clinical management of infants with T cell lym-
phopenia at birth. The wider implementation of newborn
screening for SCID is likely to increase the number of ba-
bies with low TRECs and T cell lymphopenia at birth,
some of whom will be heterozygous for LoF FOXN1 vari-
ants. Our study shows that these subjects can have a sus-
tained CD8þ T cell lymphopenia and may be at higher
risk of infections, especially in early childhood. For most,
however, the clinical and immunological abnormalities
tend to improve with time. Three of the subjects reported
in this study received HSCT, but none of them attained
T cell reconstitution, and one died of transplant-related
toxicity. These data indicate that HSCT is not a curative
treatment for individuals with FOXN1 haploinsufficiency,
consistent with the thymus-intrinsic role of the molecule.
However, the observation that a few babies with heterozy-
gous LoF FOXN1 variants developed serious infections
suggests careful clinical monitoring and adoption ofican Journal of Human Genetics 105, 1–13, September 5, 2019 11
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T cell lymphopenia at birth. In particular, in our series,
recurrent and/or serious infections were documented in 2
out of 21 infants identified with a positive newborn
screening (P8, P14), but in all 3 children in whom hetero-
zygous FOXN1 variants were identified only later in life,
based on a positive clinical history and documented
T cell lymphopenia. It is possible that in the first group
of infants the prompt use of adequate preventive measures
helped reduce the risk of infections. Future prospective
studies may better define the reasons underlying pheno-
typic heterogeneity of FOXN1 haploinsufficiency and
possibly guide treatment on a case-by-case basis. Whether
thymus transplantation may be needed in extremely se-
vere cases remains to be seen. Furthermore, studies in
mice indicate that decreased Foxn1 expression is associated
with accelerated loss of thymic architecture and func-
tion.5,7 Whether FOXN1 haploinsufficiency in aging hu-
mans will lead to accelerated thymic involution, restriction
of the T cell repertoire, and increased risk of infections and
autoimmunity remains to be studied.Supplemental Data
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